BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


View Clinical Trials from BioPharm Insight

Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.

HEPLISAV-B™ - Our Lead Product Candidate

HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.

SD-101 - Cancer Immunotherapy

We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.

Immune-Mediated Diseases

TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma

 Key Statistics

Ownership: Public

Web Site: Dynavax Technologies Corporation
Symbol: DVAX

 Company News
Dynavax Technologies Corporation (DVAX) Reports Fourth Quarter And Year End 2014 Financial Results 3/5/2015 10:08:57 AM
Dynavax Technologies Corporation (DVAX) Announces Second Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B 3/2/2015 8:59:29 AM
Dynavax Technologies Corporation (DVAX) To Present At Cowen and Company 35th Annual Health Care Conference 3/2/2015 8:57:14 AM
Dynavax Technologies Corporation (DVAX) To Present At The 2015 RBC Capital Markets' Global Healthcare Conference 2/19/2015 3:02:47 PM
Dynavax Technologies Corporation (DVAX) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/13/2015 12:42:34 PM
Dynavax Technologies Corporation (DVAX) Secures $40 Million Credit Facility With Hercules Technology Growth Capital 12/29/2014 10:14:26 AM
Berkeley's Dynavax Technologies Corporation (DVAX) Secures $40 Million Credit Facility 12/29/2014 6:05:21 AM
Dynavax Technologies Corporation (DVAX) Announces Webcast Of R&D Day 12/9/2014 1:34:00 PM
Dynavax Technologies Corporation (DVAX) And AstraZeneca PLC (AZN) To Advance TLR9 Agonist For Treatment Of Asthma Into Phase 2a Clinical Study 12/8/2014 10:47:40 AM
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014 6:08:30 AM